odevixibat

FDA Drug Profile — Bylvay, BYLVAY

odevixibat is listed in the FDA National Drug Code directory with 16 NDC codes, marketed under brand names including Bylvay, BYLVAY. Available dosage forms: capsule, capsule, coated pellets.

Drug details

Generic Name
odevixibat
Brand Names
Bylvay, BYLVAY
Application Number
NDA215498
Sponsor
Ipsen Biopharmaceuticals, Inc.
NDC Codes
16
Dosage Forms
CAPSULE, CAPSULE, COATED PELLETS
Routes
ORAL
Active Ingredients
ODEVIXIBAT

Indications and Usage

1 INDICATIONS AND USAGE BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 12.5 , 14.1 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) 1.1 Progressive Familial Intrahepatic Cholestasis (PFIC) BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC. Limitations of Use BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) protein [see Clinical Pharmacology (12.5) and Clinical Studies (14.1) ]. 1.2 Alagille Syndrome (ALGS) BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.